Psychotropics and Hepatic Issues: Nonalcoholic Fatty Liver Disease

Psychopharmacology and Psychiatry Updates

English - July 01, 2021 16:00 - 12 minutes - 17.1 MB - ★★★★★ - 232 ratings
Medicine Health & Fitness Science mentalhealth psychiatry psychopharmacology Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Alzheimer's Disease: Can We Lower the Risk?

Next Episode: Managing Neuroleptic Malignant Syndrome: An Evidence-Based Update

How important are ALT and AST abnormalities when prescribing psychotropics? Should you adjust dosing in patients with elevated ALT and AST? Does inflammation alter drug kinetics?

Faculty: Jonathan Meyer, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.

Learn more about our memberships here Earn 1 CME: Use of Psychotropics in Patients With Hepatic Issues Diagnosis and Impact on Drug Metabolism of Nonalcoholic Fatty Liver Disease: Steatosis and Nonalcoholic Steatohepatitis